Nowigence, which is working to simplify the challenges of learning, believes it has created a solution to bring order to information overload for college students. The company’s cloud-based app, Pluaris, allows individuals, teams and enterprises to quickly distill knowledge from massive amounts of public and private textual data. This positions the platform for opportunity in … Continue reading “NetworkNewsBreaks – Nowigence’s Pluaris App Helps Synthesize, Present Information to College Students in Easily Understandable Way”
Apple (NASDAQ: AAPL), an American multinational technology company, was featured in a recent analysis report that discussed last week’s iPhone 12 product drop. The report, written by LikeFolio Founder Andy Swan, reads, “The iPhone 12 lineup dropped on Tuesday. Here’s the word on the social street: Consumers prefer iPhone 12 higher-end models. In 2019, we … Continue reading “NetworkNewsBreaks – Apple Inc. (NASDAQ: AAPL) Featured in Analysis Report”
The private, plant-based extraction company boasts roster of leaders worth noting CEO served decade-plus in corporate leadership roles across the natural products, agriculture, cannabis sectors Team of qualified experts plus cutting-edge extraction technology means Pure Extracts is set for long-term strategic distribution, product innovation If leaders are, as a Forbes article notes, “the power and … Continue reading “Pure Extract Technologies Inc. Exec Team Offers Decades of Impressive Experience; Represents Power, Intellect Behind Organization”
The safety of a novel combined advanced breast cancer treatment has proven to be excellent, BriaCell announced at a major breast cancer conference The monotherapy (i.e. drug on its own) clinical trial showed positive anti-tumor activity in patients with advanced breast cancer and metastases Further information about the efficiency of the Bria-IMT/KEYTRUDA combined treatment will … Continue reading “BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Breast Cancer Treatment Confirms Positive Anti-Tumor Activity”
BriaCell Therapeutics Corp. is working to develop the first off-the-shelf personalized immunotherapy for advanced breast cancer Clinical data reveals an excellent safety profile and potent anti-tumor activity for Bria-IMT in advanced breast cancer patients Combination study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in advanced breast cancer patients is ongoing Symposium covers the … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Key Updates of Immuno-Oncology Tech at 2018 San Antonio Breast Cancer Symposium”
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Bria-IMT Clinical Data at San Antonio Breast Cancer Symposium”
Shares of Soleno Therapeutics (NASDAQ: SLNO) are up 5% following the company’s news this morning that it has received a newly-issued patent (9,757,384) from the U.S. Patent and Trademark Office protecting the use of pharmaceutical formulations of diazoxide and its salts, including the company’s diazoxide choline controlled-release tablet (DCCR), to reduce one or more aggressive … Continue reading “NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Obtains New US Patent for DCCR to Treat PWS, SMS”
Soleno Therapeutics (NASDAQ: SLNO) shares are up 11% on news that the company has received the minutes from a scientific advice meeting from the U.S. Food and Drug Administration (FDA) regarding Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi syndrome (PWS). The company previously submitted data from a phase II study of DCCR in … Continue reading “NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Surges on Positive Guidance from FDA for DCCR in Prader-Willi Syndrome”
